… We analyzed relevant clinical trials reporting the efficacy and toxicity profile of PARP inhibitors
in patients with advanced OC. We estimated hazard ratios (HRs), incidences, risk ratios (…

… PARP inhibitors are a novel targeted anti-cancer drug and a large number of clinical studies
on PARP inhibitors … to evaluate the efficacy and safety of PARP inhibitors in advanced-stage …

… This review summarizes the clinical data surrounding FDA-approved PARP inhibitors,
indications, efficacy, safety, dosing, financial considerations, and pearls for selecting the optimal …

… Poly(ADP-ribose) polymerases (PARP) are proteins responsible for DNA … PARP inhibitors
(PARPi) are able to interact with the binding site for PARP cofactor (NAD+) and trapping PARP …

… of the efficacy of PARP inhibitors in TNBC (… efficacy of PARP inhibitors combined with
carboplatin-paclitaxel (PFS: HR 0.73, 95% CI [0.60–0.88]), which confirmed that PARP inhibitors …

… efficacy and safety in this age group. Therefore, the aim of this systematic review and
meta-analysis is to determine if PARP inhibitors, … safety profile of PARP inhibitors in this …

… Purpose: Poly ADP ribose polymerase (PARP) inhibitors can … evaluates the efficacy and
safety of PARP inhibitors (PARPis… -analysis discussed the efficacy and safety of various PARPis …

… The objective of this study was to compare the antitumor efficacy and safety between the
PARP inhibitor group and the chemotherapy group. The primary outcomes of this meta-analysis …

… who can benefit from PARP inhibition. In addition, our results emphasize the essential role
of genetic assessment for optimal patient selection for PARP inhibition. Notably, mCRPC …

… the efficacy and safety of PARP inhibitors in breast cancer patients as compared to
chemotherapy. PARP inhibitors were … However, PARP inhibitors increased the risk of grade 3–4 …